ATRA

7.25

5.69% 0.39

Dopo l'orario di chiusura: 7.24 -0.010 -0.14%

Atara Biotherapeutics Inc (ATRA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ATRA Giù? Forum Previsione

Precedente Chiudi:

$6.86

Aprire:

$6.97

Volume 24 ore:

28,314

Relative Volume:

0.14

Capitalizzazione di mercato:

$42.48M

Reddito:

$100.44M

Utile/perdita netta:

$-133.16M

Rapporto P/E:

-0.2814

EPS:

-25.76

Flusso di cassa netto:

$-94.85M

1 W Prestazione:

+5.07%

1M Prestazione:

-15.60%

6M Prestazione:

-25.41%

1 anno Prestazione:

-53.97%

Intervallo 1D:

$6.6701

$7.25

Intervallo di 1 settimana:

$5.94

$7.25

Portata 52W:

$5.40

$20.81

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Nome

Atara Biotherapeutics Inc

Settore

Healthcare (1171)

Industria

Biotechnology (675)

Telefono

805-623-4211

Indirizzo

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Dipendente

153

Cinguettio

@Atarabio

Prossima data di guadagno

2024-11-18

Ultimi documenti SEC

ATRA's Discussions on Twitter

Confronta ATRA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ATRA Atara Biotherapeutics Inc	7.25	42.48M	100.44M	-133.16M	-94.85M	-25.76
VRTX Vertex Pharmaceuticals Inc	504.77	129.62B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	666.87	72.91B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	604.96	36.76B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.76	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	259.19	27.86B	3.32B	-860.46M	-1.04B	-8.32

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-11-09	Downgrade	Evercore ISI	Outperform → In-line
2023-11-09	Downgrade	H.C. Wainwright	Buy → Neutral
2023-11-09	Downgrade	Mizuho	Buy → Neutral
2022-07-20	Downgrade	Citigroup	Neutral → Sell
2022-07-13	Downgrade	JP Morgan	Overweight → Neutral
2022-07-13	Downgrade	Stifel	Buy → Hold
2022-05-10	Downgrade	Citigroup	Buy → Neutral
2021-05-13	Aggiornamento	JP Morgan	Neutral → Overweight
2020-12-09	Downgrade	Citigroup	Buy → Neutral
2020-12-08	Reiterato	H.C. Wainwright	Buy
2020-11-10	Reiterato	H.C. Wainwright	Buy
2020-06-30	Iniziato	Evercore ISI	Outperform
2020-06-15	Iniziato	H.C. Wainwright	Buy
2020-04-23	Aggiornamento	Citigroup	Neutral → Buy
2019-11-08	Downgrade	JP Morgan	Overweight → Neutral
2019-09-27	Downgrade	Goldman	Neutral → Sell
2019-09-16	Downgrade	Jefferies	Buy → Hold
2019-06-04	Aggiornamento	Citigroup	Sell → Neutral
2019-05-30	Iniziato	ROTH Capital	Buy
2019-05-23	Iniziato	Stifel	Buy
2019-01-23	Iniziato	Mizuho	Buy
2018-04-10	Iniziato	JP Morgan	Overweight
2018-03-16	Iniziato	Guggenheim	Neutral
2018-03-05	Reiterato	Jefferies	Buy
2018-02-28	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2018-02-15	Downgrade	Citigroup	Neutral → Sell
2018-01-03	Aggiornamento	Citigroup	Sell → Neutral
2017-10-06	Ripresa	Goldman	Neutral

Mostra tutto

Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie

Mar 13, 2025

Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Mar 13, 2025

Mar 12, 2025

Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group - Defense World

Mar 12, 2025

Mar 11, 2025

Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement - TipRanks

Mar 11, 2025

Mar 10, 2025

Atara Biotherapeutics: Q4 Earnings Snapshot - The Bakersfield Californian

Mar 10, 2025

Mar 09, 2025

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 09, 2025

Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes - TipRanks

Mar 09, 2025

Mar 07, 2025

Atara Biotherapeutics Reports 2024 Financial Results - TipRanks

Mar 07, 2025

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - BioSpace

Mar 07, 2025

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop - Simply Wall St

Mar 07, 2025

Mar 06, 2025

Nguyen AnhCo, CEO of Atara Biotherapeutics, sells $23,307 in stock By Investing.com - Investing.com Australia

Mar 06, 2025

Atara biotherapeutics EVP and CFO Eric Hyllengren sells $8,473 in stock By Investing.com - Investing.com South Africa

Mar 06, 2025

Atara biotherapeutics EVP and CFO Eric Hyllengren sells $8,473 in stock - Investing.com Australia

Mar 06, 2025

Mar 05, 2025

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is i - GuruFocus.com

Mar 05, 2025

Atara biotherapeutics EVP sells $7,409 in common stock - Investing.com India

Mar 05, 2025

Nguyen AnhCo, CEO of Atara Biotherapeutics, sells $23,307 in stock - Investing.com India

Mar 05, 2025

Mar 04, 2025

Trading (ATRA) With Integrated Risk Controls - Stock Traders Daily

Mar 04, 2025

Mar 03, 2025

Atara Biotherapeutics Inc To Cut 50% Of Workforce -March 03, 2025 at 05:26 pm EST - Marketscreener.com

Mar 03, 2025

Feb 27, 2025

Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet - MSN

Feb 27, 2025

Feb 26, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Feb 26, 2025

Feb 21, 2025

(ATRA) Investment Analysis - Stock Traders Daily

Feb 21, 2025

Feb 14, 2025

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - Finansavisen

Feb 14, 2025

Feb 12, 2025

Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online

Feb 12, 2025

Feb 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - Longview News-Journal

Feb 11, 2025

How the (ATRA) price action is used to our Advantage - Stock Traders Daily

Feb 11, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation - Markets Insider

Feb 11, 2025

Feb 10, 2025